Solid Tumor Clinical Trials

104 studies are recruiting for solid tumor in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

   Background: All childhood cancers are rare, but some are called very rare. Very rare cancers are diagnosed in 2 or fewer out of 1 million people each year. Researchers want to gather data so they can learn more about these very rare cancers. They hope to use the data to develop future treatments. O…

   Stage

   Not phased

   Ages

   0 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07489378 on ClinicalTrials.gov

2. FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers

   The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07638371 on ClinicalTrials.gov

3. Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors

   The purpose of the study is to find out the usefulness and safety of a dye called Indocyanine Green (ICG for short). This dye will be used to help the surgeon find lymph nodes draining solid tumors inside the abdomen that need to be removed. This may also help the surgeon to find if the cancer has …

   Stage

   EARLY_Phase 1

   Ages

   Up to 20

   Site

   Lurie Children's Hospital, Chicago, Illinois

   Locations

   3 in total

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT05645523 on ClinicalTrials.gov

4. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

   The goal of the Monotherapy Dose Escalation phase (Part 1) of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors.…

   Stage

   Phase 1

   Ages

   19 and older

   Site

   University of Arkansas Medical School, Little Rock, Arkansas

   Locations

   20 in total

   Run by

   NiKang Therapeutics, Inc.

   See if you can join NCT06586957 on ClinicalTrials.gov

5. Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

   Background: Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small percentage of these tumors are familial. Researchers want to study these changes in biological samples from people with rare tumors in order t…

   Stage

   Not phased

   Ages

   0 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Locations

   3 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03739827 on ClinicalTrials.gov

6. Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors

   This is an open-label phase I dose-escalation study to evaluate the safety of partially human leukocyte antigen (HLA)-matched multi tumor-associated antigen-specific T cell (TAA-T) therapy following lymphodepleting conditioning with or without local tumor ablation for pediatric and adult patients w…

   Stage

   Phase 1

   Ages

   1 to 70

   Site

   Children's National Hospital, Washington D.C., District of Columbia

   Run by

   Children's National Research Institute

   See if you can join NCT05238792 on ClinicalTrials.gov

7. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

   Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA Santa Monica Hematology Oncology, Santa Monica, California

   Locations

   22 in total

   Run by

   Astellas Pharma Inc

   See if you can join NCT07094204 on ClinicalTrials.gov

8. SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET

   This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of [225Ac]Ac-FL-261, a targeted radioligand therapy directed at c-MET, in participants with advanced or metastatic solid tumors. Phase 1 will identify the recommended dose t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Full-Life Technologies Investigational Site, Minneapolis, Minnesota

   Locations

   2 in total

   Run by

   Full-Life Technologies UK Limited

   See if you can join NCT07873450 on ClinicalTrials.gov

9. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   25 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

10. A Study of Freeze-Dried Miracle Fruit (MiraBurst) on Participants Receiving Cancer Treatment

    This study is for people with a diagnosis of solid tumor cancer who are experiencing changes in taste perception due to cancer treatment. Changes in taste perception, also known as dysgeusia, is a frequent side effect of cancer treatment and can significantly impacts quality of life. These alterati…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Cleveland Clinic Foundation, Cleveland, Ohio

    Run by

    Case Comprehensive Cancer Center

    See if you can join NCT07419581 on ClinicalTrials.gov

11. A Study of DS-3939a in Participants With Solid Tumors

    The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Highlands Oncology Group (Hog) - Fayetteville, Fayetteville, Arkansas

    Locations

    76 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT07739966 on ClinicalTrials.gov

12. A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

    The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Adventist Health Glendale, Glendale, California

    Locations

    20 in total

    Run by

    Teligene US

    See if you can join NCT06010342 on ClinicalTrials.gov

13. Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

    The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with soma…

    Stage

    Phase 1

    Ages

    2 to 18

    Site

    Lucile Packard Children's Hospital at Stanford, Palo Alto, California

    Locations

    9 in total

    Run by

    ITM Solucin GmbH

    See if you can join NCT06441331 on ClinicalTrials.gov

14. Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

    The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the stud…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Hartford Healthcare (Data Collection), Hartford, Connecticut

    Locations

    10 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04165772 on ClinicalTrials.gov

15. A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

    The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the acti…

    Stage

    Phase 2

    Ages

    1 and older

    Site

    Children's Hospital of Los Angeles (Data Collection Only), Los Angeles, California

    Locations

    16 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05985161 on ClinicalTrials.gov

16. A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

    This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UC San Diego Moores Cancer Center, La Jolla, California

    Locations

    49 in total

    Run by

    Genentech, Inc.

    See if you can join NCT06619587 on ClinicalTrials.gov

17. DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer

    The purpose of this study is to improve ways of providing mental health support to Spanish-speaking Latino participants who have cancer and experience depression, insomnia, and fatigue. Investigators will test a special mental health intervention called DESCANSO/REST (Depresión/Depressed Mood, Cans…

    Stage

    Not phased

    Ages

    21 to 100

    Site

    Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    8 in total

    Run by

    Ponce Medical School Foundation, Inc.

    See if you can join NCT07225088 on ClinicalTrials.gov

18. Dabrafenib and/or Trametinib Rollover Study

    This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by…

    Stage

    Phase 4

    Ages

    18 to 100

    Site

    Novartis Investigative Site, Toronto, Ontario

    Locations

    38 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT03340506 on ClinicalTrials.gov

19. STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

    This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 [PD-1]) in advanced unresectable or metastatic tumors. The Phase 2…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    14 in total

    Run by

    STORM Therapeutics LTD

    See if you can join NCT06975293 on ClinicalTrials.gov

20. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

    This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Scottsdale, Scottsdale, Arizona

    Locations

    15 in total

    Run by

    Tango Therapeutics, Inc.

    See if you can join NCT06810544 on ClinicalTrials.gov

21. Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

    This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn …

    Stage

    Not phased

    Ages

    Any age

    Site

    Children's Hospital of Alabama, Birmingham, Alabama

    Locations

    164 in total

    Run by

    Children's Oncology Group

    See if you can join NCT00736749 on ClinicalTrials.gov

22. SMP-3124LP in Adults With Advanced Solid Tumors

    An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Cedars Sinai Medical Center, Los Angeles, California

    Locations

    13 in total

    Run by

    Sumitomo Pharma America, Inc.

    See if you can join NCT06526819 on ClinicalTrials.gov

23. Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

    This is a study that will enroll patients with cancer who have tumors that may have spread. The patients will know what medication they are being given. There will be 2 parts to the study. For the first part of the study only one medication will be taken, and the dose changed to a higher dose over …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas Health Science Center at San Antonio, San Antonio, Texas

    Run by

    Lei Zheng

    See if you can join NCT07086768 on ClinicalTrials.gov

24. A Study of ASP3082 in Adults With Advanced Solid Tumors

    This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D. This study will be in 2…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center, Duarte, California

    Locations

    68 in total

    Run by

    Astellas Pharma Inc

    See if you can join NCT05382559 on ClinicalTrials.gov

25. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner Health- MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    49 in total

    Run by

    Institut de Recherches Internationales Servier

    See if you can join NCT05786924 on ClinicalTrials.gov